Merrimack Pharmaceuticals To Present Phase I Data On MM-302 And Preclinical Data On Companion Diagnostics Both For The Treatment Of HER2-Positive Breast Cancer
Research presented at 2012 SABCS examines cardiac safety profile of MM-302, a new HER2-targeted Liposomal Doxorubicin Agent.
MM-302 is a nanotherapeutic encapsulation of doxorubicin with anti-HER2 antibody fragments attached to its surface. MM-302 specifically targets cancer cells that overexpress the ErbB2 (HER2) receptor, releasing doxorubicin within the cell and limiting uptake into normal cells.
"Merrimack believes MM-302 has the potential to achieve better efficacy than current standards of care and lessened risk of cardiac toxicity relative to free doxorubicin," said
Poster Overview:
- A Phase 1 Study of MM-302, a HER2-targeted Liposomal Doxorubicin, in Patients with Advanced, HER2-positive (HER2+) Breast Cancer (Abstract #: P5-18-09)
- Poster Session 5: Treatment - HER2-Targeted Therapy
Friday, December 7, 2012 5:00 - 7:00 p.m. CT , Exhibit Hall A-B
- Poster Session 5: Treatment - HER2-Targeted Therapy
- A Novel 64Cu-Liposomal PET Agent (MM-DX-929) Predicts Response to Liposomal Chemotherapeutics in Preclinical Breast Cancer Models (Abstract #: P4-02-05)
- Poster Session 4: Detection/Diagnosis - Molecular, Functional and Novel Imaging
Friday, December 7, 2012 7:00 - 9:00 a.m. CT , Exhibit Hall A-B
- Poster Session 4: Detection/Diagnosis - Molecular, Functional and Novel Imaging
- Quantification of HER2 Expression at the Single Cell Level and HER2 Intratumoral Heterogeneity of Breast Cancer Tissue Samples Using Automated Image Analysis (Abstract #: P1-07-03)
- Poster Session 1: Prognostic and Predictive Factors — Biomarkers, Methods
Wednesday, December 5, 2012 - 5:00 —
7:00 p.m. CT , Exhibit Hall A-B
- Poster Session 1: Prognostic and Predictive Factors — Biomarkers, Methods
About
Forward-Looking Statement
Any statements in this press release about future expectations, plans and prospects for Merrimack constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially from those indicated by such forward-looking statements. Merrimack anticipates that subsequent events and developments will cause its views to change. However, while Merrimack may elect to update these forward-looking statements at some point in the future, Merrimack specifically disclaims any obligation to do so.
SOURCE
News Provided by Acquire Media